Trials / Terminated
TerminatedNCT00264134
Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Kentuckiana Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
Detailed description
A phase I/II dose escalating study to determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | |
| DRUG | Irinotecan | |
| DRUG | Carboplatin |
Timeline
- Start date
- 2003-06-01
- Completion
- 2005-10-01
- First posted
- 2005-12-12
- Last updated
- 2010-01-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00264134. Inclusion in this directory is not an endorsement.